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Abstract—Clinicians are interested in the estimation of robust
and relevant genetic signatures from gene sequencing data.
Many machine learning approaches have been proposed trying
to address well-known issues of this complex task (feature or
gene selection, classification or model selection, and prediction
assessment). Addressing this problem often requires a deep
knowledge of these methods and some of them demand high
computational resources that may not be affordable. In this
paper, an exhaustive study that includes different types of feature
selection methods and classifiers is presented, providing clinicians
an useful insight of the most suitable methods for this purpose.
Predictions assessment is performed using a bootstrap cross-
validation strategy as an honest validation scheme. The results
of this study for six benchmark datasets show that filter or
embedded methods are preferred, in general, to wrapper methods
according to their better statistical significant results, in terms
of accuracy, and lower demand for computational resources.
I. INTRODUCTION
Machine learning (ML) and predictive modeling approaches
are progressively being applied to data mining in personalized
medicine, research field that relies on selecting optimal ther-
apies based on the context of patient’s clinical and genetic
signature. Many studies are nowadays making use of ML
procedures in prediction and prognosis of complex traits [1],
[2]. In particular, there is a huge investment of resources in
cancer research since the identification of genetic signatures
correlated with clinical outcome remains as a challenging task
in clinical assistance [3], [4], [5], [6], [7]
Nevertheless, the use of gene expression profiles in the
estimation of prognosis models to find genetic signatures is
a complex task in ML. It usually involves different steps
that are not always easy to perform for clinicians, or even
researchers, due mainly to the great variety of procedures and
methods available in the literature, and the high-computing
resources required by most of them. Feature (or gene) se-
lection, classification and model selection, and prediction
assessment are the three classical steps involved in the search
of genetic signatures using ML approaches [8]. This family of
procedures takes as input gene expression profiles from both
Next Generation Sequencing (NGS) and DNA microarrays
experiments [9], [10], [11].
Given the importance of these three steps involved in the
estimation of genetic signatures, the impossibility of clini-
cians to test every ML method, and the high computational
resources requirements, many authors have proposed different
approaches trying to find molecular signatures with good
prediction accuracy. In the feature selection step (genes to
be included in the prognosis model), methods such as Partial
Least Squares (PLS) regression [12], Information Gain (IG)
[13], Minimum-Redundancy Maximum-Relevance (mRMR),
and ReliefF [14] are among the statistical techniques proposed
to address the problem. On the other hand, wrapper methods
such as Stepwise Forward Selection (SFS) [15], [16], Ant
Colony optimization [17], and evolutionary models [18], [19],
[20], [21], [22] have been applied as heuristic methods from
the computational intelligence perspective. With regard to
classification model selection, different algorithms have been
studied for the identification of differentially expressed genes
in genomic data. Classification methods such as Multilayer
Perceptron (NN) [23], [24], [15], Support Vector Machines
(SVM) [25], Naive Bayes (NB) [26], k-Nearest Neighbour
(kNN) [27], Decision Trees (DT) [28], and RF (Random For-
est) [29] have been used in recent studies. Finally, prediction
assessment refers to the performance of the predictive models.
As few patient samples are typically available in genomic
data, resampling techniques are a suitable methodology. In
this sense, any dimensionality reduction technique should be
performed within each resampling step in order to estimate
prediction errors in a completely independent test set. This
process is known as honest performance assessment [30], a
necessary process if we are looking for generalizable results
in independent cohorts, issue that has been overlooked in
several works [15], [31], [32], [33]. On the other hand,
honest validation strategies are presented in [8] and [34].
Specifically, in [8] the .632+ bootstrap method is highlighted
for high-dimensional genomic studies and a number of existing
bootstrap methods are compared (out-of-bag estimation and a
bootstrap cross-validation (BCV) method [35]).
Despite all the extensive work that has been done in this
research area, there is no conclusive results on which ML
TABLE I: Information about the six databases analysed.
Dataset #Genes #Samples “normal” “cancer”
West ER 7129 49 25 24
Breast 24481 78 34 44
Leukaemia 7129 72 25 47
Lung 12533 181 150 31
Colon 2000 62 22 40
Prostate 12600 102 50 52
method performs better in order to estimate genetic signatures
with relevance in the clinical practice. Up to date, these
three steps have not yet been analyzed in a single work
and tested over different datasets. Additionally, an extension
of the classical evolutionary approach to carry out feature
selection is presented. This procedure is considered a type
of wrapper method. Therefore, this exhaustive analysis aims
to help clinicians by providing a tool (or combination of
FS procedures and classification algorithms) that may offer
relevant results in terms of robustness, size and biological
relevance of the genetic signature.
The rest of the paper is structured as follows. Section II
shows the databases used within this study. Section III-A
describes the FS techniques tested in this work to obtain
a subset of genes and estimate prediction errors. Section
III-B presents the methodology of our approach. Section III-C
describes several machine learning models used to predict
the clinical outcomes and Section IV shows the experimental
results over different databases. Finally, Section V provides
the final conclusions of this paper.
II. DATASETS
Six free public high-dimensional microarray datasets12 have
been used within this work. Although NGS clearly seems to be
the predominant technology in the near future of biomedical
research [36], expression arrays were selected because are still
cheaper and easier when used in clinical research [37], [38],
[39], [40], [41]. In fact, from a practical point of view, ML
procedures need to be fed with expression profiles in matricial
format independently of the sequencing technology (NGS or
microarray). The information of each dataset is shown in Table
I, and each is related to the study of a specific cancer: breast,
leukaemia, lung, colon, and prostate cancer diseases.
The West ER dataset analyses primary breast tumours in
relation to estrogen receptor (ER) status; the Breast dataset
was reported for patients’ outcome prediction related to breast
cancer disorder; the Leukaemia dataset contains measures that
correspond to Acute Lymphoblastic Leukaemia (ALL) and
Acute Myeloid Leukaemia (AML) samples; the Lung dataset
has samples for two subtypes of lung cancer such as malignant
pleural mesothelioma (MPM) and adenocarcinoma (ADCA);
the Colon dataset with healthy samples versus patients diag-
nosed with colorectal cancer, and, finally, the Prostate dataset
1http://datam.i2r.a-star.edu.sg/datasets/krbd/
2http://cilab.ujn.edu.cn/datasets.htm
TABLE II: Summary of the different feature selection methods
considered in this work together with some references where
they have been previously used. We propose one GA extension
denoted with *** as another wrapper method.
Filter Wrapper Embedded
CFS [43] SFS [44] SVM-RFE [45]
Cons [46] GA *** -
mRMR [47] - -
IG [48] - -
ReliefF [49], [50] - -
contains different neoplastic samples as these tumours are
among the most heterogeneous of cancers both histologically
and with respect to highly divergent clinical outcomes.
III. METHODS
A. Feature selection framework
Feature selection procedures aims to select the most sig-
nificant subset of genes, in terms of prediction accuracy, that
are correlated with a clinical outcome. Filter, wrapper, and
embedded methods are the three main categories into which
feature selection techniques can be divided [42]. In filter
methods, some statistical procedures are applied to remove
irrelevant features, as it is a method that is completely inde-
pendent of the classifier. Wrapper methods evaluate different
subsets of features within a classification algorithm comparing
their accuracy, thus requiring more computational resources in
contrast to filter methods. Finally, embedded methods could be
seen as a mix of filter and wrapper methods where the search
space is composed of the feature-selection procedure and the
classification algorithm as a whole, thus also being a classifier-
dependent method.
Table II shows the different feature selection methods im-
plemented in this paper to compare the predictive performance
of the different estimated genetic signatures. According to the
three families of methods, we considered: (i) filter methods:
Correlation-based (CFS), Consistency-based (Cons), Informa-
tion Gain (IG), Minimum-Redundancy Maximum-Relevance
(mRMR) and ReliefF; (ii) Wrapper: Stepwise Forward Se-
lection (SFS) and Genetic Algorithms (GA); (iii) Embedded:
Support Vector Machines with Recursive Feature Elimination
(SVM-RFE).
In this work, we propose an extension of classical evo-
lutionary strategies as another wrapper method to perform
feature selection by considering together the predictive per-
formance of the genetic signature and the correlation among
the features selected and the target class. GAs are a class of
optimization procedure, inspired by the biological mechanisms
of reproduction, in which a fitness function f(x) should be
maximized or minimized over a given space X of arbitrary
dimension. A simple encoding scheme representing as much of
the available information as possible was employed in which
the chromosome is a string of bits whose length is determined
by the total number of genes. Each gene is associated with one
bit in the string. If the ith bit is active (value 1), then the ith
gene is selected in the chromosome. Otherwise, a value of 0
indicates that the corresponding gene is ignored. In this way,
each chromosome represents a different genes subset. Both
the active genes and their number are generated randomly. In
all the experiments, a population size of 100 individuals was
used.
A selection strategy based on a roulette wheel and uniform
sampling was applied, while an elite count value of 10
(the number of chromosomes which are retained in the next
generation) was selected. Scattered crossover, in which each
bit of the offspring is chosen randomly, was the choice for
combining parents of the previous generation. The crossover
rate was set to 0.8. In addition to that, a traditional mutation
operator which flips a specific bit with a probability rate of
0.2 was considered. A modification which involves mutating
a random number of bits between 1 and the number of active
genes of the individual is introduced. Since it was empirically
verified that the best subsets include few features, this change
avoids an increment in the number of active features in the
last generations of the GA.
The fitness function assesses each chromosome in the
population so that it can be ranked against all the other
chromosomes. The main goal of gene subset selection is to
use fewer genes to achieve the same or better performance.
Additionally, it has been found that the combination of genes
with low redundancy among them, that is, that provide dif-
ferent information about the target class, and with a certain
resemblance to the target class can improve the performance
rates [47]. Therefore, the fitness function should contain three
terms: the misclassification error, the number of features
selected, and a redundancy measure among them. Datasets
are split into training and testing sets in order to evaluate the
generalization ability of the proposed chromosome.
Statistical techniques such as mutual information [51] give
us an idea of the correlation between a pair of features. The
mutual information between two continuous random variables
y and z is given by
I (y, z) =
∫ ∫
p (y, z) log
(
p (y, z)
p (y) p (z)
)
dy dz (1)
where p (y, z) is the joint probability density function of y
and z, and p (y) and p (z) are the marginal probability density
functions of y and z respectively. The mutual information is
symmetric.
Moreover, it is non-negative, with a zero value indicating
that the variables are independent. The more correlated two
variables are, the greater their mutual information. Advan-
tages of mutual information are that the dependency between
variables is no longer restricted to being linear and it can
handle nominal or discrete features. Although it is hard to
compute for continuous data, the probability densities can
be discretized using histograms, which are considered as
good approximations [52]. A measure which incorporates the
correlation of the features with the target class and penalizes
the redundancy among the selected features is described as
follows [47]:
corr(x) =
1
t
k∑
i=1
k∑
j=i+1
I(xj , xi)− 1
k
k∑
j=1
I(xj , C) (2)
where k is the number of features selected, C is the target
class, and t is the number of combinations among the pairs of
chromosome x analysed. Finally, the function to be minimized
is represented as follows:
fitness(x) = (1−ACC(x)) + λ kN + βcorr(x) (3)
where fitness(x) is the fitness value of the feature subset
represented by x; ACC(x) is the accuracy rate obtained by the
classifier using the test set; N is the total number of extracted
features; finally, corr(x) defines the correlation among the
features and the target class, with the aim of avoiding the
redundancy in the feature vector (Equation 2). The parameters
λ and β can take values in the interval (0, 1) and were
empirically chosen to be 0.4 and 0.25, respectively.
Therefore, if two subsets achieve the same performance
while containing different numbers of features, the subset with
fewer features is preferred. We also prefer the mixture of fea-
tures that are less redundant among them, which is considered
a good quality for classification tasks. Nevertheless, among
the three terms - error, feature subset size, and correlation -
the first one is our major concern.
B. Validation scheme
In this paper, an honest validation strategy is applied with
the aim of obtaining a final subset of genes with high pre-
diction capabilities. Stratified boostrap cross validation was
chose as validation procedure since its good behaviour in
estimating misclassification error with microarray datasets
has been previously demonstrated in [35], [53]. A high-level
description of our methodological approach is shown in Figure
1 as well as a brief pseudocode of the algorithm is described
in Algorithm 1. In concrete, the developed procedure executes
a 50-bootstrap resampling as external validation and 5-k-fold
for internal validation techniques. Thus, this scheme will lead
us to find subsets of features with high generalization rates
in the prediction stage, as this is essential for determining the
probability of suffering from a specific condition.
Moreover, in the case of wrapper methods, Welch’s t-test
[54] is applied assuming that the two classes (the patient
does or does not have cancer) have unknown and unequal
variances, because it is not advisable to use the basic form if
we are unsure whether the requirements of the test are satisfied
[42]. The top 200 of the total number of genes are retained
according to the p-value descending sort, which will be the
input of a wrapper method feature-selection procedure.
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Fig. 1: Honest validation scheme used in the feature-selection
procedure and prediction error estimation.
Algorithm 1 Pseudocode of our methodological approach
1: {initialization}
2: [Train, Test]{1..50} ⇐ BCV (dataset, 50)
3: FeatureSelectionMethods =[SFS,GA,CFS, ... ,SVM-RFE]
4:
5: for all method m in FeatureSelectionMethods do
6: {first-step: feature selection process}
7: for i = 1→ 50 do
8: TRi ⇐ Train[i]
9: if (IsWrapperMethod(m)) then
10: TR Reducedi ⇐ Ttest(TRi)
11: [IntV ali, Featuresi] ⇐ ExecWrapper(m,TR Reducedi)
//involves execution of a classification method
12: else if (IsFilterMethod(m)) then
13: [Featuresi]⇐ ExecFilter(m,TRi)
14: [IntV ali]⇐ ExecClassificationMethod(TRi, Featuresi)
15: else
16: [Featuresi]⇐ ExecEmbedded(m,TRi)
17: [IntV ali]⇐ ExecClassificationMethod(TRi, Featuresi)
18: end if
19: end for
20: InternalV alidation⇐ mean(IntV ali)
21:
22: {second-step: model validation}
23: for i = 1→ 50 do
24: Ti ⇐ Test[i]
25: ExtV ali ⇐ Accuracy(Ti, Featuresi)
26: end for
27: ExternalV alidation⇐ mean(ExtV ali)
28: end for
C. Classification models
Several standard and well-known classification models have
also been tested in this paper: Linear Discriminant Analysis
(LDA), Support Vector Machines (SVM), k-Nearest Neigh-
bours (kNN), Naive-Bayes (NB), C-MANTEC (CM) [55] as
a constructive neural network model, and a standard Multilayer
Perceptron (NN). Nested cross-validation is used to perform
model selection after doing a grid-search over the parameters
of each machine learning model. In this sense, this procedure
implies a huge effort in terms of computational and time
resources, since in the case of wrapper methods many different
subsets of features are evaluated in each iteration. Therefore,
the authors propose to adjust the parameters of each method
by using the top 200 variables after sorting the p-values
obtained by the application of Welch’s t-test. As a result of this
suggested parameter estimation method, every configuration is
labelled by an accuracy measure in a reasonable time. Finally,
the parameter configuration with the highest average result in
the outter folds is kept to fit the model to the training samples.
The accuracy measure is obtained through the .632+ bootstrap
method [56], as it is highlighted for high-dimensional genomic
studies.
IV. RESULTS
Figure 2 presents a summary of the final results obtained
over each dataset. For each one, the bar diagram represents
the performance of eight feature-selection procedures analysed
in this paper: two different wrapper methods (SFS and GA),
five different filter methods (CFS, Cons, IG, mRMR, and
ReliefF), and one embedded method (SVM-RFE). This per-
formance is computed after averaging the accuracy obtained
with six machine-learning classifiers (LDA, SVM, kNN, NB,
CM, and NN). In general, filter and embedded methods are
distinguished by the most accurate results in contrast to wrap-
per methods, independently of the cancer microarray dataset
analysed. In concrete, mRMR emerges as the one with the
best performance in three out of six analysed cancer datasets
(Leukaemia, Lung, and Colon). Therefore, the results suggest
the use of filter or embedded methods instead of wrapper
methods, since the latter are more highly computationally
demanding, leading to lower performance results on average.
Regarding the six cancer microarray datasets analysed, for
three of them (the Leukaemia, Lung, and Prostate datasets), a
very good classification result is obtained independently of the
feature-selection procedure (over a 90%). On the other hand,
the West ER and Colon datasets present good classification
results (over 80%) while the Breast cancer dataset appears
to be the most difficult problem as a success rate of only
65% is achieved, which could lead us to think that more
patient samples are needed to estimate gene-expression-based
predictors.
A. Classification models’ performance
Regarding the classifier models’ performance, a deeper anal-
ysis has been carried out and is represented in Figures 3 and 4.
In particular, Figure 3 shows a pairwise analysis of the number
of times that one classifier is statistically significant better
than another one according to the multiple comparison test.
The thickness of the lines connecting the different classifiers
indicates four categories in which the comparison was done:
classifiers that are better than the other less than four times are
discarded and not represented on the graph; those that are four
to six times better than the other are represented by the thinnest
line on the graph; those that are seven to nine times better than
the other are indicated with a middle thickness line; finally, the
last category represents classifiers that are better than the other
more than nine times (shown in the graph with the thickest
line). The results suggest that the kNN, NN, or NB classifier
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Fig. 2: Performance comparison (after averaging the accuracy
of six machine learning classifiers) for eight feature selection
procedures over six different cancer microarray datasets.
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Fig. 3: Pairwise graph showing the number of times that the
performance of a given classifier is statistically significant in
comparison to other classifiers.
should be used rather than LDA and the rest. LDA is the only
classifier that does not outperform any other classifier (does
not reach the category that is seven to nine times better), so
in principle it could be discarded as a classifier for the DNA
microarray analysis.
Finally, Figure 4a) shows the percentage value of the
number of times (occurrences) that a given classifier leads
to statistically significant different results in comparison to a
control group (the lowest in performance) computed among
all analysed cases (different datasets and FS procedures),
while Fig. 4b) shows a similar analysis but for different FS
procedures among all datasets and classifiers. The histogram
shown in 4a) indicates that kNN is the preferred classifier as
it does outperform other classifiers almost 60% of the time,
while LDA behaves quite poorly as it achieves the best results
less than 20% of the time.
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Fig. 4: Summary of results. (a) Percentage value of the
number of times (occurrences) that a given classifier leads
to statistically significant different results in comparison to
a control group computed for all analysed cases (different
datasets and FS procedures). (b) Analysis similar to before
as before but for different FS procedures performed over all
datasets and classifiers.
B. Honest validation scheme
The use of an honest validation scheme is relevant, as
performance results could be very optimistic otherwise. In
this sense, and according to the results shown in Figure 2,
we selected three a priori more difficult datasets (West ER,
Breast, and Colon) in order to perform a detailed analysis
using SFS and GA as FS procedures. Table III shows the
performance results of the LDA and SVM classifier models
for each dataset with and without using an honest validation
scheme. As expected, the behaviour of FS procedures is very
optimistic if no honest validation is applied, independently
of the classifier used. The final accuracy measures vary from
honest validation schemes (H+) to non-honest ones (H−) ap-
proximately a 20% (West ER), 16−20% (Breast), and 5−18%
(Colon). Regarding the overfitting problem in the feature
selection, an overfitting index (OI) was computed to analyse
how much this effect affects the FS procedures, classifiers,
and datasets. It was computed as OI = 1 − (H+/H−), and
averaged across datasets and classifiers, where OI considerably
above zero will point out a clear overfitting scenario. The
results of the overfitting index were OI = 0.2297 for the SFS
procedure and OI = 0.1845 for the GA. Therefore, previous
articles that did not use an honest validation scheme presented
over-optimistic results as no test set was kept apart from the
FS procedure.
C. Robustness of the FS procedures
An important aspect of the FS procedure is the variability
observed in the set of selected subsets of genes in different
executions of a given algorithm. In order to quantify this,
we compute a robustness index for each FS procedure used,
taking into consideration the subset of genes obtained for every
resampling of the dataset. First, the absolute frequency for
each gene is computed in order to retain those genes selected
at least 5% of the time . Then the set of selected genes is
sorted in descending order according to the relative frequency,
discarding those genes for which the cumulative frequency is
greater than 80%. Finally, the robustness measure is calculated
as the average of the relative frequencies of the resulting genes.
TABLE III: Performance comparison among two different
wrapper methods (SFS and GA) and two classifiers (LDA and
SVM) using three datasets (West ER, Breast and Colon). The
results shown correspond to the accuracy of each classification
method using the honest validation scheme proposed (H+) in
this work and without using it (H−).
SFS GA
Classifier H+ H− H+ H−
West ER
LDA 73.29 95.14 81.16 99.52
SVM 77.78 96.63 79.58 99.32
Breast
LDA 63.35 79.45 66.23 95.10
SVM 64.27 82.36 66.72 97.78
Colon
LDA 81.69 86.04 83.70 92.45
SVM 78.39 88.27 78.61 95.28
Figure 5 shows the robustness value obtained for each
dataset, depending on the FS procedure used. ReliefF could
be considered the most robust FS procedure according to our
analysis, since it leads to the highest robustness values for
three datasets with competitive values for the other three.
Moreover, IG and mRMR are a step backward in comparison
to ReliefF but they also have competitive robustness values. On
the other hand, the remainder of the FS procedures have values
of less than 0.5 for almost all of the datasets, and thus it can be
derived that on several executions of the algorithm, a different
subset of genes will be obtained. It should be noted that there is
no clear correlation between the robustness and the accuracy
measure, since the most robust method (ReliefF) is not the
same as the most accurate technique (SVM-RFE). Between
the wrapper methods, GA overcomes SFS in both robustness
and accuracy. To further confirm the results shown in the
figure, permitting a more direct comparison of the robustness
of the FS procedures, we compute a weighted average of
the results shown by averaging the observed values re-scaled
in relationship to the maximum value obtained within each
dataset (an average value of 1 would indicate that the FS
method obtained the best robustness index for all datasets),
obtaining the following values: ReliefF: 0.87179; IG: 0.78078;
mRMR: 0.64941; GA: 0.61396; SFS: 0.48686; CFS: 0.45904;
SVM-RFE: 0.43212; Cons: 0.30266.
D. Number of selected genes
The number of genes obtained by the different FS proce-
dures studied varies depending on several factors. According
to the raw data results shown in Table IV, it can be appreciated
that the SFS, GA, and Cons procedures are more aggressive
in the gene-selection procedure, as few genes are kept in the
final solutions. In the case of the SFS procedure, this could
be explained by the nature of the algorithm, as it begins
from solutions with only one gene and then iteratively adds
new genes, while the performance is statistically significantly
better than in the previous iteration. In a similar way, the
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Fig. 5: Robustness measure for each FS procedure among the
different resamplings of each dataset, computed taking into
account the variability of the selected genes.
GA procedure includes in its fitness function the desired
characteristics of the solutions, maximizing the accuracy result
while at the same time keeping those configurations with a
smaller number of genes.
In comparison to wrapper methods (SFS and GA), filter
and embedded methods are independent from the classification
model. As these methods usually retain many more genes in
their solutions, we established the following cut-off criteria:
if the solution has more genes than the number of samples
available in the dataset, then only the first #samples/8
genes are kept (genes are sorted according to their suitability).
Thus, there are some cases of FS procedures (i.e., SVM-RFE,
mRMR, ReliefF, ...) where the number of selected genes is
constant for all resamplings (the standard deviation is equal
to zero in these cases). This criterion was set, firstly in order
to reduce the number of selected genes per resampling and
secondly in order to apply similar criteria over all filter and
embedded methods so that a fair comparison could be made.
V. CONCLUSION
Based on the results discussed above, it is time to ask
whether it is worth testing every ML model available to find
relevant genetic signatures from gene expression data or not.
In Figure 2 we presented a summary of the average accuracy
results for all of the analysed datasets. The results of this
study indicate the presence of three less complex datasets
(Leukaemia, Lung, and Prostate) for which, independently
of the FS and classification method used, the accuracy is
always larger than 84%. Moreover, the use of honest validation
schemes leads to less overfitting in the feature selection (an
overfitting index was computed by dividing the accuracy with
the proposed honest validation scheme and without using
an honest validation scheme and then averaged across the
three selected datasets and the two classification algorithms
analysed).
TABLE IV: Number of selected genes obtained
(mean±standard deviation) for the eight analysed feature
selection procedures (SFS, GA, CFS, Cons, IG, mRMR,
ReliefF and SVM-RFE) for three cancer microarray datasets
(West ER, Breast and Leukaemia).
West ER Breast Leukemia
SFS 2.51±0.74 3.10±1.20 2.25±0.63
GA 4.21±1.08 10.04±2.30 3.63±0.98
CFS 8.88±10.96 10.28±9.05 30.02±23.33
Cons 2.12±0.44 3.36±0.56 1.84±0.51
IG 6.00±0.00 9.00±0.00 9.00±0.00
mRMR 6.00±0.00 9.00±0.00 9.00±0.00
ReliefF 6.00±0.00 9.00±0.00 9.00±0.00
SVM-RFE 6.00±0.00 9.00±0.00 9.00±0.00
Regarding the classification models, the results shown in
Figures 3 and 4 suggest that kNN and NN classifiers could
be considered more robust methods independently of the FS
method used and the dataset. Nevertheless, other classification
techniques such as SVM or CM, which require the adjustment
of several parameters, could lead to the achievement of similar
results after a fine-tuning in the parameter estimation stage.
Regading the FS methods, the embedded SVM-RFE and
three other filter methods (IG, mRMR, and ReliefF) behave
qualitatively better than the rest of the methods, indicating
a superior performance in comparison to wrapper methods.
Further, taking into account that wrapper methods tend to be
more computationally intensive, the previous results clearly
suggest an advantage of filtering (or embedded) FS schemes.
In relation to the number of selected genes, SFS and Cons
lead to more restricted sets, but with the disadvantage of worse
performance, indicating that except when the size of the final
set is a very important factor, these two FS procedures should
not be the preferred option.
Finally, the overall conclusion of the present study will de-
pend on finding the right balance between the cost associated
to carry out a wide analysis like this one and the performance
that we may be interested in. In general, filter and embedded
methods may be more suitable rather than wrapper ones, as
they lead to more robust results in terms of both percentages
of better statistical significant results and overfitting effects,
and are also less computationally intensive. Some of these FS
methods in combination with kNN or NN classifiers could
lead to robust and relevant genetic signatures in the studied
disorder, thus being a suggested set of methods to be tried
first by clinicians.
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